An initiative by
In knowledge partnership with

#ReasonToSmile

#ReasontoSmile is a Cancer Awareness Initiative by Reliance Nippon Life Insurance Company (RNLIC) in association with the Kokilaben Dhirubhai Ambani Hospital (KDAH) to create awareness around this dreaded disease.

We espouse the philosophy that Every Life Matters and in keeping with this philosophy, RNLIC shall contribute Re. 1 per participant in the #ReasontoSmile quiz. You can make a difference by participating in this quiz and referring your family and friends to also participate.

We look forward to your patronage.

Did you know?

  • Cancer is the 2nd biggest killer in India[1]
  • India has the 3rd highest number of cancer cases among in the world[2]
  • In India, in every 8 men & 1 in every 9 women could be diagnosed with some form of cancer during their lifetime of around 75 years[3]
  • 10 lakhs new cases of cancer diagnosed in India every year[4]
  • Breast and Cervical cancers are the most common cancers diagnosed amongst women in India[4]
  • 71% of cancer related deaths occur between the ages 30-69 years [5]

Quiz Spread Million Smiles

1. Chances of early stage cancer survival are
2. Chances of late stage cancer survival are
3. Is proactive early stage cancer detection possible?
4. Mammography is the cancer test for
5. Pap test is a check-up done for
I agree to the Terms & Conditions

Thank you for helping us contribute to the cause of Cancer.

To contribute further, please share this below link with your friends and family and help make a bigger difference.

Every Life Matters

Leading Oncologists demystify aspects of cancer, early warning symptoms, treatment and care necessary to successfully overcome this ailment.

Know more about us

Reliance Nippon Life Insurance Company is amongst the leading private sector life insurance companies in India in terms of individual WRP (weighted received premium) and new business WRP. The company is one of the largest non-bank supported private life insurers with over 10 million policyholders, a strong distribution network of over 700 branches and more than 65,000 advisors as on March 31, 2018. The company holds Claim Settlement Ratio of 95.17% as on March 31, 2018.

Rated amongst the Top 3 Most Trusted Life Insurance Service Brands by Brand Equity‘s Most Trusted Brands Survey 2018, the company’s vision is “To be a company people are proud of, trust in and grow with; providing financial independence to every life we touch.” With this in mind, Reliance Nippon Life caters to five distinct segments, namely Protection, Child, Retirement, Saving & Investment, and Health; for individuals as well as Groups/Corporate entities.

Reliance Nippon Life Insurance Company is a part of Reliance Capital, one of India's leading private sector financial services companies, which ranks among the top private sector financial services and non-banking companies, in terms of net worth. Reliance Capital has interests in asset management and mutual funds, stock broking, life & general insurance, proprietary investments, private equity and other activities in financial services.

In FY'16, post the enabling regulations, Nippon Life increased its stake in Reliance Life from 26% to 49%, subsequent to the receipt of all regulatory approval. Nippon Life Insurance, also called Nissay, with 20.5% market share is Japan's largest private life insurer with revenues of Rs. 4,12,809 crore (US$ 65 Billion) and profits of over Rs. 29,849 crores (US$ 4.7 billion) as of Mar 31, 2017. The Company, with over 31 million policies in Japan, offers a wide range of products, including individual and group life and annuity policies through various distribution channels and mainly uses face-to-face sales channel for its traditional insurance products. The company primarily operates in Japan, North America, Europe and Asia and is headquartered in Osaka, Japan. It is ranked 111th among the global Fortune 500 firms in 2017.

Established in 2009, Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute (KDAH) is one of India’s most advanced quaternary care institutions. It has brought the world's best technology and treatment protocols to India, making comprehensive healthcare available, accessible and affordable to all. In fact, the hospital has been ranked the No. 1 multispecialty hospital in Mumbai and the Western Region three years in row by The Times of India in 2016 2017 and 2018, and is the only hospital in Mumbai to receive the four most coveted accreditations: JCI (Joint Commission International, USA), NABH (National Accreditation Board for Healthcare, India), CAP (College of American Pathologists, USA) and NABL (National Accreditation Board for Laboratories, India).

With the finest medical professionals and a full-time specialist system (FTSS) model, KDAH has systematically bridged many a gap in the healthcare fabric. Pioneering efforts include the first comprehensive centre for liver transplant and the first integrated centre for children's cardiac care in western India; the robotic surgery programme; the centres for rehabilitation and sports medicine; and the initiative to open 18 cancer care centres in rural Maharashtra. Indeed, KDAH has 15 centres of excellence, 27 specialty departments and 25 super specialist clinics—its best-in-class diagnostic and surgical solutions and cutting-edge equipment enable the successful treatment of complex health conditions across the board.

Having delivered world-class outcomes, KDAH is now a destination of choice for healthcare seekers in India and abroad.